Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
3.950
+0.140 (3.67%)
At close: Aug 1, 2025, 4:00 PM
3.930
-0.020 (-0.51%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 279 employees as of December 31, 2024. The number of employees decreased by 46 or -14.15% compared to the previous year.
Employees
279
Change (1Y)
-46
Growth (1Y)
-14.15%
Revenue / Employee
$509,412
Profits / Employee
-$224,093
Market Cap
33.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | 432 | 85 | 24.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KPTI News
- 23 hours ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Karyopharm to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - PRNewsWire
- 2 months ago - Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PRNewsWire
- 2 months ago - These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
- 2 months ago - Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification - PRNewsWire
- 3 months ago - Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 - PRNewsWire